Autres langues Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 01/09/2026			Varia. 5j.	Varia. 1 janv.
14,16 ^USD	+3,96%		+5,99%	-19,04%

26/08	Les ETF en baisse, les contrats à terme sur actions mitigés avant l'ouverture mercredi suite à la publication des données sur l'inflation	MT
26/08	Les contrats à terme sur actions américaines stables avant l'ouverture, entre données d'inflation et attente des résultats de Nvidia	MT

Autres langues

26/08	Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release
26/08	US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results
26/08	Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints
26/08	Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer
26/08	Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
25/08	Afternoon Meeting: Wall Street exige resultados
25/08	Wall Street Wants Receipts
25/08	Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
25/08	Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines…
13/08	Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
12/08	Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
12/08	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
05/08	Summit Therapeutics Expands Ivonescimab Global Development Program With Phase II/III Harmonigu1 Study In First-Line Bladder Cancer
05/08	Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
27/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
23/07	Summit Therapeutics Q2 Adjusted Loss Widens
23/07	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17
23/07	Summit Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
23/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
22/07	Summit Therapeutics Announces Updated Overall Survival Results From Global Phase III HARMONi Clinical Trial Of Ivonescimab Plus Chemotherapy
22/07	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
16/07	Kalshi to allow bets on clinical trials, FDA decisions
16/07	Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
14/07	Summit Therapeutics Inc. Signs Agreement to Sell Ridinilazole to Biossil, Inc